-+ 0.00%
-+ 0.00%
-+ 0.00%

Enlivex Therapeutics Announces Investor Webinar To Discuss Interim Data From Phase I/II Allocetra Trial In Knee Osteoarthritis On March 5, 2025, At 11:00 a.m. ET

Benzinga·03/04/2025 21:32:14
Listen to the news

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a live investor webinar on March 5, 2025, at 11:00 a.m. ET to discuss the positive interim six-month data from the Phase I stage of its ongoing randomized, multi-country Phase I/II Allocetra™ trial in patients with moderate to severe knee osteoarthritis.

The exclusive event, hosted by RedChip Companies, will feature the Company's Chief Executive Officer, Oren Hershkovitz Ph.D., who will provide a detailed review of the interim results, which demonstrated a statistically significant 47.0% average reduction in reported pain (P=0.0001) and a 46% improvement in joint function at six months post-treatment. Additionally, 83% of treated patients were still considered responders to treatment at six months, which the Company believes highlights the durability and sustained efficacy of Allocetra™ as a potential breakthrough treatment for osteoarthritis. Importantly, no serious adverse events were reported, reinforcing the favorable safety profile of Allocetra™.